An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment. Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists. Results: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions. Conclusions: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [10]
In the citing paper
“Currently, two agents, pirfenidone and nintedanib are approved for this disease and both have been shown to reduce the rate of decline in lung function in patients with IPF.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [10]
In the citing paper
“there remain only two pharmacologic treatments recommended for use – nintedanib and pirfenidone [9–11]. Additionally, both of these medications are only conditionally recommended based on moderate confidence in effect estimates”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [10]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Self-citationRaghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
Self-citationPrednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Sanderson, S., Tatt, I. D., & Higgins, J. P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym018 · Cited by 1,531
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationHigh-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Self-citationPirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Self-citationPrevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Self-citationHigh prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Raghu, G., Freudenberger, T. D., Yang, S., Curtis, J. R., Spada, C., Hayes, J., Sillery, J. K., Pope, C. E., & Pellegrini, C. A. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00037005 · Cited by 643
Self-citationA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Schünemann, H. J., Jaeschke, R., Cook, D. J., Bria, W. F., El-Solh, A. A., Ernst, A., Fahy, B. F., Gould, M. K., Horan, K. L., Krishnan, J. A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-197st · Cited by 577
Self-citationIncreased Prevalence of Gastroesophageal Reflux in Patients with Idiopathic Pulmonary Fibrosis
TOBIN, R. W., POPE, C. E., PELLEGRINI, C. A., EMOND, M. J., SILLERY, J., & RAGHU, G. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.6.9804105 · Cited by 570
Self-citationTreatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Self-citationRandomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 505
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Self-citationIdiopathic Pulmonary Fibrosis and Emphysema
Mejía, M., Carrillo, G., Rojas-Serrano, J., Estrada, A., Suárez, T., Alonso, D., Barrientos, E., Gaxiola, M., Navarro, C., & Selman, M. (2009) · Chest · doi:10.1378/chest.08-2306 · Cited by 468
Self-citationA Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis
Kubo, H., Nakayama, K., Yanai, M., Suzuki, T., Yamaya, M., Watanabe, M., & Sasaki, H. (2005) · Chest · doi:10.1378/chest.128.3.1475 · Cited by 440
Lee, J. S., Ryu, J. H., Elicker, B. M., Lydell, C. P., Jones, K. D., Wolters, P. J., King, T. E., & Collard, H. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0138oc · Cited by 437
Self-citationOku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 436
Lee, J. S., Collard, H. R., Anstrom, K. J., Martinez, F. J., Noth, I., Roberts, R. S., Yow, E., & Raghu, G. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70105-x · Cited by 413
Self-citationInhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
OLSCHEWSKI, H., ARDESCHIR GHOFRANI, H., WALMRATH, D., SCHERMULY, R., TEMMESFELD-WOLLBRÜCK, B., GRIMMINGER, F., & SEEGER, W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9810008 · Cited by 410
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · PubMed · Cited by 358
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Self-citationSildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis
Collard, H. R., Anstrom, K. J., Schwarz, M. I., & Zisman, D. A. (2007) · Chest · doi:10.1378/chest.06-2101 · Cited by 254
Self-citationPARK, S.-H., SALEH, D., GIAID, A., & MICHEL, R. P. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.2.9607123 · Cited by 244
Han, M. K., Bach, D. S., Hagan, P. G., Yow, E., Flaherty, K. R., Toews, G. B., Anstrom, K. J., & Martinez, F. J. (2013) · Chest · doi:10.1378/chest.12-1594 · Cited by 227
Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia
Corte, T. J., Keir, G. J., Dimopoulos, K., Howard, L., Corris, P. A., Parfitt, L., Foley, C., Yanez-Lopez, M., Babalis, D., Marino, P., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0446oc · Cited by 226
Self-citationNakazato, H., Oku, H., Yamane, S., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01758-2 · Cited by 187
Filion, K. B., Chateau, D., Targownik, L. E., Gershon, A., Durand, M., Tamim, H., Teare, G. F., Ravani, P., Ernst, P., Dormuth, C. R., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304738 · Cited by 183
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35110-9 · Cited by 181
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38125-x · Cited by 179
Chambers, R. C. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707603 · Cited by 175
Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis
Thabut, G., Christie, J. D., Ravaud, P., Castier, Y., Dauriat, G., Jebrak, G., Fournier, M., Lesèche, G., Porcher, R., & Mal, H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-11-200912010-00004 · Cited by 172
Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-139 · Cited by 151
Jain, R., Shaul, P. W., Borok, Z., & Willis, B. C. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0353oc · Cited by 151
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
Hoeper, M. M., Halank, M., Wilkens, H., Günther, A., Weimann, G., Gebert, I., Leuchte, H. H., & Behr, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00213911 · Cited by 151
Self-citationPulmonary fibrosis is associated with an elevated risk of thromboembolic disease
Sprunger, D. B., Olson, A. L., Huie, T. J., Pérez, E. R. F., Fischer, A., Solomon, J., Brown, K. M., & Swigris, J. J. (2011) · European Respiratory Journal · doi:10.1183/09031936.00041411 · Cited by 146
Lung Transplantation for Idiopathic Pulmonary Fibrosis
Mason, D. P., Brizzio, M. E., Alster, J. M., McNeill, A. M., Murthy, S. C., Budev, M. M., Mehta, A. C., Minai, O. A., Pettersson, G., & Blackstone, E. H. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.04.096 · Cited by 131
HOMMA, S., AZUMA, A., TANIGUCHI, H., OGURA, T., MOCHIDUKI, Y., SUGIYAMA, Y., NAKATA, K., YOSHIMURA, K., TAKEUCHI, M., KUDOH, S., et al. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02132.x · Cited by 127
Self-citationNavaratnam, V., Fogarty, A. W., McKeever, T., Thompson, N., Jenkins, G., Johnson, S. R., Dolan, G., Kumaran, M., Pointon, K., & Hubbard, R. B. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-203740 · Cited by 119
Raghu, G., & Meyer, K. C. (2012) · European Respiratory Journal · doi:10.1183/09031936.00211311 · Cited by 118
Self-citationMadden, B. P., Allenby, M. I., Loke, T.-K., & Sheth, A. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.01.013 · Cited by 117
Schünemann, H. J., Osborne, M., Moss, J., Manthous, C., Wagner, G., Sicilian, L., Ohar, J., McDermott, S., Lucas, L., & Jaeschke, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0126st · Cited by 115
Self-citationVenous Thromboembolism and Risk of Idiopathic Interstitial Pneumonia: A Nationwide Study
Sode, B. F., Dahl, M., Nielsen, S. F., & Nordestgaard, B. G. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1951oc · Cited by 113
Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis
Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O. (2010) · Lung · doi:10.1007/s00408-009-9209-8 · Cited by 92
A pilot study of aerosolized N‐acetylcysteine for idiopathic pulmonary fibrosis
TOMIOKA, H., KUWATA, Y., IMANAKA, K., HASHIMOTO, K., OHNISHI, H., TADA, K., SAKAMOTO, H., & IWASAKI, H. (2005) · Respirology · doi:10.1111/j.1440-1843.2005.00725.x · Cited by 78
Keating, D., Levvey, B. J., Kotsimbos, T. C., Whitford, H. M., Westall, G. P., Williams, T., & Snell, G. I. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.10.042 · Cited by 70
Force, S. D., Kilgo, P., Neujahr, D. C., Pelaez, A., Pickens, A., Fernandez, F. G., Miller, D. L., & Lawrence, C. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.08.055 · Cited by 69
Neurohr, C., Huppmann, P., Thum, D., Leuschner, W., von Wulffen, W., Meis, T., Leuchte, H., Baumgartner, R., Zimmermann, G., Hatz, R., et al. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01071.x · Cited by 64
Self-citationMinai, O. A., Sahoo, D. H., Chapman, J. T., & Mehta, A. C. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.02.002 · Cited by 58
De Oliveira, N. C., Osaki, S., Maloney, J., Cornwell, R. D., & Meyer, K. C. (2012) · Interactive CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivr085 · Cited by 51
The Dangers of Stopping a Trial Too Early
Briel, M., Bassler, D., Wang, A. T., Guyatt, G. H., & Montori, V. M. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.01412 · Cited by 49
Raghu, G. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1842ed · Cited by 42
Self-citationThe big clinical trials in idiopathic pulmonary fibrosis
Luppi, F., Spagnolo, P., Cerri, S., & Richeldi, L. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283567ff9 · Cited by 42
Self-citationEndothelin Antagonism and Its Role in the Treatment of Hypertension
Moorhouse, R., Webb, D. J., Kluth, D., & Dhaun, N. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0380-1 · Cited by 36
Results of Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients
Algar, F. J. A., Espinosa, D., Moreno, P., Illana, J., Cerezo, F., Álvarez, A., Baamonde, C., Redel, J., Vaquero, J. M., Santos, F., et al. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.05.046 · Cited by 26
Cited by
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationRaghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Self-citationMartinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Self-citation
Metadata
- Authors
- Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., Johkoh, T., Martinez, F. J., Myers, J., Protzko, S. L., Richeldi, L., Rind, D., Selman, M., Theodore, A., Wells, A. U., Hoogsteden, H., & Schünemann, H. J.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07
- Volume
- 192
- Issue
- 2
- Pages
- e3-e19
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1938547050
- Cited by
- 1,916
- References
- 69
- Citations by year
- 2026: 57 · 2025: 89 · 2024: 138 · 2023: 159 · 2022: 214 · 2021: 248 · 2020: 213 · 2019: 203 · 2018: 211 · 2017: 194 · 2016: 152 · 2015: 35
- FWCI
- 156.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, treatment guidelines, antifibrotic therapy, nintedanib, pirfenidone, pulmonary fibrosis progression, lung transplantation, extracorporeal membrane oxygenation, clinical practice guideline update
- MeSH terms
- Humans, Societies, Medical, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.